Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™ March 28, 2018 07:30 AM Eastern Daylight Time PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present clinical and pre-clinical data on the company’s investigational medicines for the treatment of chronic hepatitis B infection (ARC-520 and ARO-HBV) and liver disease associated with alpha-1 antitrypsin deficiency (ARO-AAT), at The International Liver Congress™ 2018, the annual meeting of the European Association for the Study of the Liver (EASL), being held in Paris from April 11-15, 2018. https://www.businesswire.com/news/home/...-Liver#.WruBGQGrnSo.twitter
Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress™ April 11, 2018 07:00 AM Eastern Daylight Time https://www.businesswire.com/news/home/20180411005375/en/ Key results include the following:
One HBeAg-negative patient serocleared HBsAg post ARC-520 Mild ALT changes off ARC-520 therapy coincided with sustained host responses in 2/3 HBeAg- positive and 2/5 HBeAg-negative patients A single dose of ARC-520 in combination with ETV reduced HBsAg for up to 44 weeks Multiple doses of ARC-520 resulted in additional HBsAg reductions in all patients by as much 5.3 Log10 ARC-520 in combination with ETV was effective at rapidly suppressing HBV DNA
American Thoracic Society (ATS) 2018 International Conference – San Diego, May 18-23, 2018
May 21, 9:15 a.m.-4:15 p.m. PDT – Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver a poster presentation titled, “Targeting αENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis.” In this presentation, Dr. Bush will present new preclinical data on ARO-ENaC, formerly referred to as ARO-Lung1, targeting the epithelial sodium channel alpha subunit (αENaC) for the treatment of cystic fibrosis.
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $10 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a clinical study. Amgen is evaluating AMG 890 in a Phase 1 clinical study designed to assess its safety in volunteers with elevated levels of lipoprotein (a) (Lp(a)). Emerging research has shown that elevated levels of Lp(a) are strongly associated with cardiovascular disease. AMG 890 is an RNAi therapeutic designed to lower Lp(a) for the treatment of cardiovascular disease.
Arrowhead plans to seek federal regulatory approval to start clinical trials on three more products before the end of the year. Two are cardiometabolic — referring to cardiovascular disease and diabetes — and one targets cystic fibrosis, said Vincent Anzalone, vice president of finance and investor relations. A prospective drug against kidney cancer is on the agenda for 2019 and there is “a handful of others beyond that,” he said, all built on the targeted RNAi molecule platform.
Thread abonnieren
